The $350M Bet on a Protein Most People Have Never Heard Of
Electra Therapeutics just raised $350 million in one of 2026's biggest biotech IPOs, betting on a protein family most people have never heard of. The upsized deal signals serious investor appetite, but the real test is still ahead.
A Biotech Nobody Rings the Nasdaq Bell
A year ago, most biotech investors couldn't have picked Electra Therapeutics out of a lineup. On September 18, 2026, the company walked onto the Nasdaq Global Select Market and raised $350 million in one of the year's biggest biotech IPOs. The ticker: ETRA. The vibe: confident.
The deal was originally set at about 21.67 million shares. But demand was strong enough that underwriters bumped it up to 23.3 million shares, priced right at the midpoint of the $14–$16 range. When Wall Street asks for more shares of your company, that's the biotech equivalent of a restaurant with a two-hour wait: people clearly want what you're serving.
Jefferies, TD Cowen, Evercore ISI, and Cantor ran the books. The underwriters also grabbed a 30-day option to buy another 3.5 million shares, which could push total proceeds even higher.
So what exactly is Electra selling that got investors this excited?
The Immune System's "Do Not Eat" Signs
Electra's platform targets a family of proteins called SIRPs (Signal Regulatory Proteins). Think of SIRPs as the badges that certain immune cells flash to avoid getting attacked by your own body. In healthy people, this system works fine. But in some diseases, the wrong cells start wearing those badges, and the immune system goes haywire.
Electra's lead drug, ipsoprubart (also called ELA026), is a monoclonal antibody designed to bind three different types of SIRPs at once. Instead of broadly suppressing the immune system (the blunt-hammer approach that most treatments use), ipsoprubart selectively takes out the specific rogue cells driving hyperinflammation. It's the difference between fumigating your whole house and surgically removing the one nest of wasps in the attic.
A Rare Disease With Almost No Options
Ipsoprubart's main target is a condition called secondary hemophagocytic lymphohistiocytosis, or sHLH for short. It's a rare, life-threatening inflammatory syndrome where the immune system essentially turns on the body with overwhelming force. Patients can deteriorate fast, and current treatments are limited.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
